Want to see HK:8189 full AI Analyst Report?

Tianjin TEDA Biomedical Engineering Co. Ltd. Class H (8189) Price & Analysis

2 Followers

8189 Stock Chart & Stats

HK$0.40

HK$0.00(0.00%)

At close: Jan 09 4:00 PM EST

HK$0.40

HK$0.00(0.00%)

Day’s Range― - ―

52-Week RangeHK$0.11 - HK$0.43

Previous CloseN/A

Volume305.00K

Average Volume (3M)1.69M

Market Cap

HK$376.54M

Enterprise ValueHK$85.30

Total Cash (Recent Filing)HK$65.29M

Total Debt (Recent Filing)HK$108.79M

Price to Earnings (P/E)―

Beta0.13

Next Earnings

Apr 01, 2027

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.01

Shares Outstanding1,436,400,000

10 Day Avg. Volume2,631,000

30 Day Avg. Volume1,692,193

Financial Highlights & Ratios

PEG Ratio-0.04

Price to Book (P/B)46.59

Price to Sales (P/S)1.12

P/FCF Ratio-9.07

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Revenue ReboundThe sharp revenue rebound indicates renewed business activity and provides a larger base from which management could pursue operating improvements, although the durability of this recovery still depends on converting sales into sustainable margins.

Positive Revenue Growth TrendReported revenue growth supports the view that demand has improved compared with the company’s prior position. Sustained top-line expansion could strengthen scale and supplier relationships if it continues across multiple reporting periods.

Biomedical Engineering FocusA biomedical engineering focus gives the company exposure to healthcare-related applications rather than purely discretionary demand. This sector orientation may support longer-term relevance if the company can develop products and achieve commercially viable execution.

Bears Say

Persistent UnprofitabilityLow and volatile gross margins, persistent operating losses, and a widening net loss indicate that revenue growth has not translated into economic profitability. Without sustained margin improvement, future expansion may continue to destroy value.

Excessive LeverageRapidly rising leverage and sharply reduced equity constrain financial flexibility. High debt exposure increases refinancing and solvency risk, while continued losses could further weaken the balance sheet and limit investment in growth.

Negative Cash GenerationFour consecutive years of negative operating cash flow, alongside deteriorating free cash flow, show that the business is not self-funding. Continued reliance on external financing can increase dilution, debt pressure, and execution risk.

8189 FAQ

What was Tianjin TEDA Biomedical Engineering Co. Ltd. Class H’s price range in the past 12 months?

Tianjin TEDA Biomedical Engineering Co. Ltd. Class H lowest stock price was HK$0.11 and its highest was HK$0.43 in the past 12 months.

What is Tianjin TEDA Biomedical Engineering Co. Ltd. Class H’s market cap?

Tianjin TEDA Biomedical Engineering Co. Ltd. Class H’s market cap is HK$376.54M.

When is Tianjin TEDA Biomedical Engineering Co. Ltd. Class H’s upcoming earnings report date?

Tianjin TEDA Biomedical Engineering Co. Ltd. Class H’s upcoming earnings report date is Apr 01, 2027 which is in 191 days.

How were Tianjin TEDA Biomedical Engineering Co. Ltd. Class H’s earnings last quarter?

Tianjin TEDA Biomedical Engineering Co. Ltd. Class H released its earnings results on Aug 31, 2026. The company reported HK$0.054 earnings per share for the quarter.

Is Tianjin TEDA Biomedical Engineering Co. Ltd. Class H overvalued?

According to Wall Street analysts Tianjin TEDA Biomedical Engineering Co. Ltd. Class H’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Tianjin TEDA Biomedical Engineering Co. Ltd. Class H pay dividends?

Tianjin TEDA Biomedical Engineering Co. Ltd. Class H does not currently pay dividends.

What is Tianjin TEDA Biomedical Engineering Co. Ltd. Class H’s EPS estimate?

Tianjin TEDA Biomedical Engineering Co. Ltd. Class H’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Tianjin TEDA Biomedical Engineering Co. Ltd. Class H have?

Tianjin TEDA Biomedical Engineering Co. Ltd. Class H has 1,436,400,000 shares outstanding.

What happened to Tianjin TEDA Biomedical Engineering Co. Ltd. Class H’s price movement after its last earnings report?

Tianjin TEDA Biomedical Engineering Co. Ltd. Class H reported an EPS of HK$0.054 in its last earnings report. Following the earnings report the stock price went down -1.961%.

Which hedge fund is a major shareholder of Tianjin TEDA Biomedical Engineering Co. Ltd. Class H?

Currently, no hedge funds are holding shares in HK:8189

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Tianjin TEDA Biomedical Engineering Co. Ltd. Class H Stock Smart Score

Underperform

Technicals

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

12.78%

Trailing 12-Months

Learn more about TipRanks Smart Score

Top Smart Score Stocks >

Company Description

Tianjin TEDA Biomedical Engineering Co. Ltd. Class H

Tianjin TEDA Biomedical Engineering Company Limited, founded in 2000 and based in Tianjin, People's Republic of China, is a diversified enterprise primarily involved in the research, development, manufacturing, and distribution of biological compound fertilizer products throughout the PRC. Its operations are organized into two main divisions: Biological Compound Fertilizers and Elderly and Health Care Services. The company's agricultural offerings encompass active fertilizers and various tailored blends of nitrogen, phosphorus, and potassium, specifically formulated to promote balanced growth for a range of crops including grains, fruits, and vegetables. Beyond agriculture, Tianjin TEDA Biomedical provides integrated care for the elderly and comprehensive health services. This includes leasing essential equipment for seniors and offering specialized consulting, advisory, and assessment solutions. Furthermore, the company develops and licenses electroencephalography (EEG) diagnosis detection services, utilizing its expertise in EEG technology for diagnostic applications. Its extensive activities also cover the research, development, production, and practical application of biomedical science and technology projects, alongside regional soil resource conditioning and remediation, and the provision of soil environmental quality standards research services.